Simvastatin and a plant galactolipid protect animals from septic shock by regulating oxylipin mediator dynamics through the MAPK-cPLA2 signaling pathway

Sepsis remains a major medical issue despite decades of research. Identification of important inflammatory cascades and key molecular mediators are crucial for developing intervention and prevention strategies. In this study, we conducted a comparative oxylipin metabolomics study to gain a comprehensive picture of lipid mediator dynamics during the initial hyper-inflammatory phase of sepsis, and demonstrated, in parallel, the efficacy of simvastatin and plant galactolipid, 1,2-di-O-α-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol (dLGG) in the homeostatic regulation of the oxylipin metabolome using a lipopolysaccharide (LPS)-induced sepsis C57BL/6J mouse model. LPS increased the systemic and organ levels of pro-inflammatory metabolites of linoleic acid including leukotoxin diols, i.e., 9,10-DHOME, 12,13-DHOME, and octadecadienoic acids, i.e., 9-HODE and 13-HODE; and arachidonic acid-derived prostanoid, PGE2, and hydroxyeicosatetraenoic acids, i.e., 8, 12- and 15-HETE. Treatment with either compound decreased the levels of pro-inflammatory metabolites and elevated pro-resolution lipoxin A4, 5(6)-EET, 11(12)-EET and 15-deoxy-PGJ2. dLGG and simvastatin ameliorated the effects of LPS-induced MAPK-dependent activation of cPLA2, cyclooxygenase-2, lipoxygenase, cytochrome P450, and/or epoxide hydrolase, lowered systemic TNF- and IL-6 levels and aminotransferase activities and decreased organ-specific infiltration of inflammatory leukocytes and macrophages, and septic shock-induced multiple organ damage. Furthermore, both dLGG and simvastatin increased the survival rates in the cecal ligation and puncture (CLP) sepsis model. This study provides new insights into the role of oxylipins in sepsis pathogenesis and highlights the potential of simvastatin and dLGG in sepsis therapy and prevention. (USA and ROC patent pending; One technology transfer to a biotech company)

 

同研究人員:Maria Karmella Apaya, Chih-Yu Lin, Ching-Yi Chiou, Chung-Chih Yang, Chen-Yun Ting and Lie-Fen Shyur
Lie-Fen Shyur

Lie-Fen Shyur

Distinguished Research Fellow

(02) 2787-2102
jaclyn@gate.sinica.edu.tw
A731, Agricultural Technology Building
Lab.
A728, Agricultural Technology Building
Tel: (02) 2787-2100
  • 07/2018- to date Distinguished Research Fellow, Agricultural Biotechnology Research Center, Academia Sinica
  • 05/2019-08/2019 Visiting Scholar of UC Davis, USA
  • 03/2008- 8/2016 Vice Director, Agricultural Biotechnology Research Center, Academia Sinica
  • 2008-2018 Research Fellow, Agricultural Biotechnology Research Center, Academia Sinica
  • 2008-2014 Coordinator of Molecular and Biological Agricultural Sciences program of Taiwan International Graduate Program (TIGP-MBAS), Academia Sinica
  • 2003-2008 Associate Research Fellow, Agricultural Biotechnology Research Center, Academia Sinica
  • 1998-2003 Assistant Research Fellow, Institute of BioAgricultural Sciences, Academia Sinica
  • 1994-1997 Postdoctoral Research Fellow, Department of Biochemistry and Biophysics, Iowa State University, USA
  • 1991-1992 Postdoctoral Research Fellow, Department of Agricultural Chemistry, National Taiwan University
  • 1990-1991 Postdoctoral Research Fellow, Department of Biochemistry, Chang Gung University


SPECIAL ACHIEVEMENT
 

  • Received US FDA approval for Zhaohe Cao (???)-based botanical drug for an Investigational New Drug (IND) for cancer therapy (2017).